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Abstract
Background: Hepatic arterial anomalies (HAAs) are not infrequently encountered during pancreatic
resections. In view of the current emergence of the robotic platform as a safe alternative to open sur-
gery in experienced centres, this study sought to determine the implications of HAAs on the safety and
oncologic outcomes of robotic pancreaticoduodenectomy (RPD).
Methods: A prospectively maintained database of patients with HAAs who underwent RPD
(RPD + HAA) at a single institution between 2008 and 2013 was retrospectively reviewed. Demographic
information and perioperative outcomes of RPD were compared for patients with and without HAAs.
Results: A total of 142 patients underwent RPD; 112 (78.9%) did not have and 30 (21.1%) did have
HAAs. The majority (90.0%) of RPDs in patients with HAAs were performed for malignant indications
and all aberrant vessels were preserved without conversion to laparotomy. There were no statistically
significant differences between RPD patients with and without HAAs with respect to preoperative
demographics, tumour characteristics, operative metrics (operative time, estimated blood loss, conver-
sion) and postoperative outcomes, including complications, length of stay and readmissions. Negative
margin (R0) rates were similar in both groups.
Conclusions: Robot-assisted pancreaticoduodenectomy is safe and feasible in patients with HAAs
and has outcomes similar to those in patients with normal arterial anatomy.
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Introduction
Hepatic arterial anomalies (HAAs) are not unusual and are
encountered in 20–45% of pancreaticoduodenectomies (PDs),
adding to the difficulty of an already technically challenging
operation.1–7 The variations in hepatic arterial blood supply
were classically delineated by Michels in 1966 and updated by
Hiatt et al. in 1994 (Table 1).3,5 The most common anomaly
according to the Hiatt et al. system of classification is a type
III variant: a replaced or accessory right hepatic artery (RHA)
that arises from the superior mesenteric artery (SMA).4 This
variant is of great concern during PD because the anomalous
vessel can course near or through the pancreatic head and pos-
terior to the common bile duct.6,8 Similarly, the less common
type V variant, in which the common hepatic artery (CHA)
arises from the SMA, can also impede dissection of the pancre-
atic head, common bile duct and gastroduodenal artery (GDA)
during PD.2 Injury to the hepatic arteries can lead to liver
ischaemia and also affect bilioenteric anastomosis because the
RHA provides the chief blood supply to the common bile
duct.1,9,10
Several series from experienced centres have demonstrated
that the emerging use of the robotic platform for PD can be a
safe alternative to the open surgery approach.11–14 The techni-
cal advantages of the robotic platform (three-dimensional
visualization, magnification and dexterity) may be useful for
This paper is associated with a video titled ‘Robotic Pancreatico-
duodenectomy with Anomalous Hepatic Arterial Anatomy’, presented at
the Annual Meeting of the AHPBA, 20–24 February 2013, Miami, Florida.
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the meticulous dissection required in PD in the presence of
HAAs.15–17 However, the method is disadvantaged by the lack
of haptic feedback, which can potentially cause vascular injury
and compromise margins.15,18 Although several reports have
established outcomes equivalent to those of open PDs in
patients with normal versus aberrant hepatic arterial anatomy
(particularly Hiatt et al. type III variants), the safety and out-
comes of robotic PD (RPD) in the presence of anomalous
hepatic arterial anatomy remain unknown.8,19–21
Materials and methods
Following University of Pittsburgh Institutional Review Board
approval, a retrospective review of a prospectively collected
database of patients submitted to RPD between 2008 and 2013
was performed. Patients who underwent RPD with HAAs
(RPD + HAA group) were identified based on operative
reports and electronic medical records. Outcomes in this group
were compared with those in RPD patients without HAAs
(RPD  HAA group). All outcomes were followed to 90 days.
Pancreatic fistulae were graded according to International
Study Group of Pancreatic Fistula (ISGPF) criteria.22 Postoper-
ative complications were graded based on the Clavien–Dindo
system of classification.23 The pancreatic and bile duct margins
were the only margins routinely assessed intraoperatively.
At the study institution, all RPD patients undergo a preop-
erative triphasic computed tomography (CT) scan. Hepatic
arterial anomalies considered relevant to a PD were a replaced
or accessory RHA or CHA, and arteries that arose in a classic
(non-aberrant) fashion but had an anomalous course similar
to that of a replaced RHA or CHA (Fig. 1).
Statistical analysis was performed using STATA Version 12.0
(StataCorp LP, College Station, TX, USA). The distribution of
continuous variables was checked for normality. The two-tailed
Student’s t-test was used to compare normally distributed vari-
ables between the normal and anomalous arterial anatomy
groups. The Wilcoxon rank-sum test was used for continuous
variables that were not normally distributed. The two-tailed
Fisher’s exact test was used to compare categorical variables.
Values are presented as the mean  standard deviation (SD)
or median with interquartile range (IQR) as appropriate. P-val-
ues of <0.05 were considered to indicate statistical significance.
Results
Prevalence of anomalous hepatic arterial anatomy
Robotic PD was performed in 142 patients, of whom 30
(21.1%) harboured HAAs (RPD + HAA group). The most
common vascular anomaly encountered was a replaced RHA
(n = 15, 50.0%) followed by a replaced CHA (n = 9, 30.0%)
(Table 2). All of the replaced RHAs and CHAs arose from the
SMA except in one case, in which the replaced CHA arose
directly from the aorta. There was a single case of an accessory
RHA coming off the GDA. Another patient had a GDA arising
from an aberrant RHA deep in the neck of the gland. In both
cases, the GDA was transected while the accessory and aberrant
RHAs were preserved. Additionally, in four patients either the
RHA (n = 3) or CHA (n = 1) took an anomalous path, cours-
ing posterior and lateral to the portal vein.
Table 1 Hepatic anatomy according to the classifications of
Michels5 and Hiatt et al.3
Michels Anatomy Hiatt et al.
I Normal (RHA and LHA
arise from the proper
hepatic artery)
I
II Replaced LHA from the LGA II
III Replaced RHA from the SMA III







V Accessory LHA from LGA II
VI Accessory RHA from the SMA III
VII Accessory LHA and
accessory RHA
IV





IX Replaced CHA from SMA V
X Replaced CHA from the LGA
Replaced CHA from the aorta VI
LGA, left gastric artery; LHA, left hepatic artery; RHA, right hepatic
artery; SMA, superior mesenteric artery.
Figure 1 Intraoperative view of a resection bed in a robotic
pancreaticoduodenectomy in a 42-year-old patient with pancreatic
head adenocarcinoma. Note the anomalous common hepatic
artery arising from the coeliac trunk and coursing posterior to the
portal vein. The tip of the suction lies on the superior mesenteric
artery, which has been skeletonized in 180 ° fashion in order to
maximize the R0 outcome. The resected specimen is shown on
the far left aspect of the field.
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Preoperative characteristics
Preoperative demographics for patients submitted to RPD with
and without anomalous hepatic arterial anatomy are summa-
rized in Table 3. No differences were observed between the
groups in demographics or final histologic diagnoses.
Operative parameters
In the RPD + HAA group, mean operative time was 501 min
and median estimated blood loss (EBL) was 250 ml. In six
patients (20.0%) EBL exceeded 500 ml. None of the HAA
RPDs required conversion to laparotomy and all aberrant or
anomalous vessels were preserved without the need for resec-
tion or reconstruction. Operating time, EBL (including EBL of
>500 ml), number of patients requiring blood transfusions,
and rates of conversion to open surgery did not differ statisti-
cally between RPDs performed with and without standard
hepatic arterial anatomy (Table 4).
Postoperative outcomes of RPDs in anomalous
hepatic arterial anatomy
Postoperative outcomes are depicted in Table 4. In the
RPD + HAA group, two deaths (90-day mortality: 6.7%) were
recorded. These were caused by biliary sepsis in one patient
and a sudden cardiac arrest that occurred outside the hospital
in another. Four RPD + HAA patients (13.3%) had a major
(Clavien Grades III and IV) complication, two of which were
pseudoaneurysms. The first pseudoaneurysm occurred in a
patient with a replaced RHA who developed a pseudoaneurysm
(in the setting of a pancreatic leak) in a branch of the inferior
pancreaticoduodenal arcade, which was treated with coil embo-
lization. The second pseudoaneurysm occurred in a patient
with a replaced CHA coming off the SMA, who developed a
pseudoaneurysm of the proper hepatic artery which was stent-
ed and then coiled. The two other major complications were
respiratory failure requiring a tracheostomy and an inferior
vena cava filter placement following a pulmonary embolus.
Eight RPD + HAA patients (26.7%) had a pancreatic leak; in
four (13.3%) patients these leaks were clinically significant IS-
GPF grade B or C leaks. There were no cases of hepatic ischae-
mia, hepatic abscess or biliary stricture. The mean length of
stay (LoS) was 9.5 days and the 90-day readmission rate was
20.0%. Postoperative outcomes including 90-day mortality,
minor and major Clavien complication rates, rates of pancre-
atic fistula, LoS and readmission rates did not differ signifi-
cantly between the groups (Table 4).
Pathologic data and oncologic outcomes of RPDs in
patients with HAAs
Of the 30 patients with HAAs, 27 (90.0%) had malignant
pathology [14 pancreatic ductal adenocarcinomas (PDACs),
seven ampullary cancers, four cholangiocarcinomas, one neuro-
endocrine tumour, and one metastatic renal cell carcinoma].
Five of the patients with PDAC had neoadjuvant therapy. Two
PDAC resections had R1 positive margins (one pancreatic neck
and one common bile duct margin). No positive margins were
incurred on any of the anomalous vessels or retroperitoneal
margins. The distribution of histologic diagnoses, receipt of
neoadjuvant therapy, incidence of positive margins, and lymph
node counts were similar between patients undergoing RPD
with anomalous and standard hepatic anatomy (Table 5).
Discussion
Variants of the hepatic arterial vasculature are not uncommon
and represent an important consideration in PD. There is a
potential risk for vascular injury, as well as oncologic concerns
for the achievement of negative margins in malignant disease.
The presence of an aberrant RHA has been shown in many stud-
ies not to impact outcomes in open PD.8,19–21,24 Descriptions of
the impacts of other less common arterial anomalies on PD are
mostly limited to review articles and small case series or
reports.6,25–29 This is the first study to examine the impact of
HAAs on the outcomes of minimally invasive PD. Despite the
lack of tactile feedback, the robotic platform was found to be safe
in this challenging setting at the present study centre.
Preoperative identification of aberrant RHA can be under-
recognized, as reported by Stauffer et al.9 Similarly, an artery
with an anomalous course is likely to be more difficult to dis-
tinguish on preoperative imaging, but carries a similar risk for
injury. The incidence of HAA in this study is in line with that
in prior reports. At the present centre, a triphasic CT (with a
dedicated arterial phase) is employed in the preoperative
workup of all patients undergoing PD when possible. Conse-
quently, borderline resectable cancers that are anticipated to
undergo major venous or arterial resection (>90 ° abutment)
Table 2 Distribution of relevant hepatic arterial anomalies
encountered in 30 of 142 patients undergoing robotic
pancreatoduodenectomy
Nature of aberrant/anomalous vessel n (%)
Replaced RHA 15 (50.0%)
Off SMA 14
Off SMA and replaced LHA from LGA 1
Replaced CHA 9 (30.0%)
Off SMA 8
Off aorta (Hiatt type VI) 1
Anomalous RHA course 3 (10.0%)
Anomalous CHA course 1 (3.3%)
Accessory RHA off GDA 1 (3.3%)
Replaced GDA off RHAa 1 (3.3%)
aAlthough this is not a classic hepatic arterial anomaly, it was included
because the RHA left the GDA and coursed lateral to the common bile
duct.
CHA, common hepatic artery; LGA, left gastric artery; LHA, left hepatic
artery; RHA, right hepatic artery; SMA, superior mesenteric artery.
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with primary end-to-end anastomosis or interposition vein
grafts are assigned to an open surgery protocol. It is likely that
the judicious use of triphasic CT and the stereotactic magnifi-
cation of the robotic platform facilitated the preservation of all
30 aberrant/anomalous hepatic arteries despite a very high per-
centage of malignant indications (90.0%). This is in line with
the low rates of sacrifice of aberrant arteries attributed to
malignant involvement reported in the literature on open
PD.8,9,19,21,24,26
The technical challenge of performing a PD in the presence of
HAA may lead to greater intraoperative blood loss and postoper-
ative complications. In two large, well-matched comparisons of
outcomes in this context with those of PDs with standard anat-
omy, Kim et al.8 and Eshuis et al.19, respectively, reported on 37
and 143 open PDs with aberrant RHAs. Both groups reported an
aberrant vessel preservation rate of >90%. Median EBL in the
cohorts with an aberrant RHA was 950 ml and 1100 ml, respec-
tively, and did not differ significantly from that in the standard
PD cohorts. Additionally, incidences of major postoperative
complications were similar. The present results corroborate these
findings, indicating that blood loss, transfusion rates and com-
plications were not compromised by the robotic approach.
Operative times for RPD + HAA were long but comparable with
those published by Kim et al.8 The present group has previously
shown precipitous reductions in RPD operative time beyond a
learning curve of 80 cases. When data for RPDs performed
before the learning curve (11 cases) are eliminated, median oper-
ative time for the RPD + HAA cohort is 451 min. Importantly,
no patients required conversion.
Although the safety of RPD has been previously estab-
lished,22 a major concern is the lack of haptic feedback and its
implications on arterial dissection, especially when the resec-
tion is performed for cancer. Margin distance remains a signif-
icant prognostic factor influencing recurrence and survival in
patients with pancreatic adenocarcinoma, and a dissection on
the peri-adventitial layers of the SMA (or an aberrant hepatic
artery) invariably improves the retroperitoneal R0 margin rate
but may increase the risk for arterial injury. Rates of post-pan-
createctomy haemorrhage (PPH) ranged from 2.7% to 14% in
three large series of PD performed with anomalous RHA and
do not differ from those in patients with normal hepatic arte-
rial anatomy submitted to PD.8,18,20 The present group
observed a rate of PPH of 6.7%, which is within these parame-
ters. When using the robotic platform, arterial injury can be
minimized by strict adherence to a no-touch technique when
dissecting around these arteries. Adequate tension can be
exerted on the surrounding tissue by the third robotic arm or
by the laparoscopic bedside assistant to allow for safe dissec-
tion. The combination of a low-energy robotic hook and the
bipolar grasper ensures the efficient handling of small uncinate
vascular branches with minimal heat dissipation to the SMA or
aberrant vessels.
Table 3 Preoperative variables in patients undergoing robotic pancreatoduodenectomy (RPD) with (RPD + HAA) and without







Age, years, mean  SD 65.9  12.7 67.7  12.6 0.476
Female, n (%) 10 (33.3%) 56 (50.0%) 0.149
BMI, kg/m2, mean  SD 27.3  6.3 27.2  5.4 0.945
CCI age-adjusted, mean  SD 4.0  2.3 4.1  2.7 0.882
CCI age-unadjusted, mean  SD 2.23  1.4 2.02  1.8 0.547
Pathology, n (%)
Malignancy 27 (90.0%) 88 (78.6%) 0.196
Histology, n (%)
PDAC 14 (46.7%) 43 (38.4%) 0.832
Ampullary adenocarcinoma 7 (23.3%) 20 (17.9%)
Cholangiocarcinoma 4 (13.3%) 5 (4.5%)
IPMN 3 (10.0%) 16 (14.3%)
Neuroendocrine tumour 1 (3.3%) 11 (9.8%)
DCA 0 4 (3.6%)
GIST 0 2 (1.8%)
Others 1a (3.3%) 11 (9.8%)
a
Renal cancer metastasis.
BMI, body mass index; CCI, Charlson Comorbidity Index; DCA, duodenal adenocarcinoma; GIST, gastrointestinal stromal tumour; IPMN, intra-
ductal papillary mucinous neoplasm; PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation.
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From an oncologic perspective, the robotic platform yielded
similar R0 margins in the contexts of equivalent tumour size,
extent of neoadjuvant therapy administered, and extent of perineu-
ral or lymphovascular invasion in both groups. Importantly, none
of the aberrant vessels were sacrificed as a result of intraoperative
injury, and none of the positive margins were retroperitoneal or
involved the aberrant or anomalous hepatic arteries. It is important
to note, however, that microscopic assessment of the aberrant or
anomalous vessel margin is challenging for the pathologist because
this margin is not as clearly defined on the resected specimen as
other ‘standardized’ margins may be. Additionally, the definition
of ‘no microscopic tumour at the margin’ was used to define R0,
Table 4 Operative and postoperative outcomes in patients undergoing robotic pancreatoduodenectomy (RPD) with (RPD + HAA) and







Operation time, min, mean  SD 500.7  105.2 529.5  103.2 0.179
Patients transfused, n (%) 3 (10.0%) 30 (26.8%) 0.194
EBL, ml, median (IQR) 250 (150–400) 300 (150–550) 0.742
EBL >500 ml, n (%) 6 (20.0%) 34 (30.4%) 0.361
Duct size, mm, mean  SD 5.3  3.8 4.9  4.3 0.659
Dilated duct (>3 mm), n (%) 16 (53.3%) 52 (46.4%) 0.532
Conversion to open surgery, n (%) 0 11 (9.8%) 0.120
Perioperative outcomes
Mortality within 90 days, n (%) 2 (6.7%) 3 (2.7%) 0.285
Complications (Clavien grade), n (%)
Grades I and II 15 (50.0%) 45 (40.2%) 0.183
Grades III and IV 4 (13.3%) 29 (25.8%)
Reoperation, n (%) 0 4 (3.6%) 0.579
Pseudoaneurysm, n (%) 2 (6.7%) 7 (6.3%) 1.00
Pancreatic leak, n (%) 8 (26.7%) 17 (15.2%) 0.177
Pancreatic leak (ISGPF grade), n (%)
No leak 22 (73.3%) 95 (84.8%) 0.324
Grade A 4 (13.3%) 8 (7.1%)
Grade B 3 (10.0%) 5 (4.5%)
Grade C 1 (3.3%) 4 (3.6%)
Delayed gastric emptying, n (%) 3 (10.0%) 26 (23.2%) 0.132
Hospital LoS, days, median (range) 9.5 (7–13) 10 (8–14) 0.297
Readmission within 90 days, n (%) 6 (20.0%) 33 (29.5%) 0.363
EBL, estimated blood loss; IQR, interquartile range; ISGPF, International Study Group of Pancreatic Fistula; LoS, length of stay; SD, standard
deviation.
Table 5 Pathology and oncologic outcomes in patients undergoing robotic pancreatoduodenectomy (RPD) with (RPD + HAA) and






Neoadjuvant therapy, n (%) 5 (18.5%) 17 (19.3%) 0.783
Tumour size, cm, mean  SD 2.5  1.4 2.8  1.5 0.742
Lymph node yield, mean  SD 22.3  7.16 17.5  7.8 0.315
Perineural invasion, n (%) 20 (74.1%) 54 (61.4%) 0.259
Vascular invasion, n (%) 21 (77.8%) 63 (71.5%) 0.803
Margin positive (R1) a, n (%) 2 (7.4%) 11 (12.5%) 0.732
aNo R2 resections.
SD, standard deviation.
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regardless of the margin distance. Both of these factors may have
influenced the high rate of R0 resection identified in this series.
Longer follow-up is needed to ensure that these short-term
oncologic surrogate outcomes translate to equivalent survival.
This study has several limitations, the most important of
which is its retrospective nature. Despite the similarity between
the groups in preoperative and pathologic characteristics, an
inherent selection bias may arise in the process of categorizing
patients for robotic platform versus open surgery. The present
group has not attempted to perform major vascular resections
or reconstructions (primary end-to-end and vein interposition)
using the robotic platform and thus procedures involving more
‘difficult’ borderline resectable tumours are usually performed
in an open fashion at this institution.
In conclusion, this single-institution study demonstrates that
RPD can be performed safely in patients with aberrant or
anomalous hepatic arterial anatomy with acceptable periopera-
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